Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Cancer|August 9, 2020
Treating acute myeloid leukemia in the modern era: A primerWilliam G Blum, Alice S Mims
Blood|April 5, 2012
RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humansAnja Troeger, Amy J Johnson, Jenna Wood, et al.
Leukemia|September 15, 2025
Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasiaDaniel Pollyea, Tessa Kerre, Dries Deeren, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2006
Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamideChristopher L Hallemeier, Mark D Girgis, William G Blum, et al.
Haematologica|October 1, 2013
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)Meir Wetzler, Dorothy Watson, Wendy Stock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 22, 2020
Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 ExpressionAlison R Walker, John C Byrd, James S Blachly, et al.
Blood Advances|October 17, 2017
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001Geoffrey L Uy, Sumithra J Mandrekar, Kristina Laumann, et al.
Journal of Hematology & Oncology|January 17, 2025
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trialJorge E Cortes, Gail J Roboz, Maria R Baer, et al.
Leukemia|January 13, 2025
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studiesNadeen Anabtawi, Deedra Nicolet, Najla Alotaibi, et al.
Leukemia|February 24, 2023
Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance studyKrzysztof Mrózek, Jessica Kohlschmidt, James S Blachly, et al.
Pageof 3